Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIZENS FINANCIAL GROUP INC/RICFG · Entity 1913 | Director | February 14, 2019 | February 15, 2019 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIZENS FINANCIAL GROUP INC/RI
Report date February 14, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,993.604 |
Reported balance
After 2019-02-14 transaction · row 1
1 source rowRow 1 · 2019-02-14 · Grant · Acquired 30.91 · Balance 60,993.604 F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan.
REGENERON PHARMACEUTICALS, INC.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,303 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 200 · Balance 17,303 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 6, 2025 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,958 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001968202-25-000007 · edgardoc.xml · derivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,958 Underlying: Common Stock · 1,958 shares Expires 2035-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 166 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-25-000007 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,748 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $1,059.28 | $2,118.56 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 17 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,582 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $1,057.38 | $2,114.76 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 16 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,584 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F16 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on October 1, 2024 at prices ranging from $1,057.28 to $1,057.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,056.68 | $3,170.04 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,586 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F15 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on October 1, 2024 at prices ranging from $1,056.55 to $1,056.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,054.90 | $3,164.70 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,589 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F14 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on October 1, 2024 at prices ranging from $1,054.76 to $1,054.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,053.45 | $4,213.80 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,592 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F13 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on October 1, 2024 at prices ranging from $1,053.06 to $1,053.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,052.44 | $4,209.76 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,596 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F12 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on October 1, 2024 at prices ranging from $1,052.37 to $1,052.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $1,051.51 | $9,463.59 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,600 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F11 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on October 1, 2024 at prices ranging from $1,051.10 to $1,051.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $1,050.60 | $6,303.60 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,609 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F10 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on October 1, 2024 at prices ranging from $1,050.27 to $1,050.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $1,049.68 | $9,447.12 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,615 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F9 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on October 1, 2024 at prices ranging from $1,049.18 to $1,049.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $1,048.54 | $12,582.48 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,624 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F8 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on October 1, 2024 at prices ranging from $1,048.00 to $1,048.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $1,047.44 | $12,569.28 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,636 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F7 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on October 1, 2024 at prices ranging from $1,047.09 to $1,047.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $1,046.53 | $9,418.77 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,648 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F6 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on October 1, 2024 at prices ranging from $1,046.14 to $1,046.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $1,045.27 | $7,316.89 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,657 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F5 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on October 1, 2024 at prices ranging from $1,045.00 to $1,045.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $1,044.62 | $9,401.58 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,664 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F4 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on October 1, 2024 at prices ranging from $1,044.14 to $1,044.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $1,043.39 | $5,216.95 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,673 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F3 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on October 1, 2024 at prices ranging from $1,043.12 to $1,043.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,042.31 | $1,042.31 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,678 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,041.35 | $3,124.05 |
DisclosureSEC source: 0001968202-24-000130 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,679 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F2 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on October 1, 2024 at prices ranging from $1,041.10 to $1,041.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 1, 2024 at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,191.02 | $4,764.08 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 20 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,682 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,190.00 | $1,190.00 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 19 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,686 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $1,189.13 | $5,945.65 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 18 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,687 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F9 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on September 3, 2024 at prices ranging from $1,189.04 to $1,189.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,188.55 | $4,754.20 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 17 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,692 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,187.95 | $3,563.85 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 16 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,696 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F8 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on September 3, 2024 at prices ranging from $1,187.86 to $1,187.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $1,186.19 | $5,930.95 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,699 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F7 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on September 3, 2024 at prices ranging from $1,186.12 to $1,186.47. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,185.77 | $4,743.08 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,704 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,184.26 | $1,184.26 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,708 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $1,183.47 | $9,467.76 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,709 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F6 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on September 3, 2024 at prices ranging from $1,183.39 to $1,183.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $1,179.62 | $9,436.96 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,717 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F5 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on September 3, 2024 at prices ranging from $1,179.52 to $1,179.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,178.69 | $4,714.76 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,725 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,177.73 | $4,710.92 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,729 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,176.82 | $4,707.28 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,733 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $1,175.66 | $9,405.28 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,737 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F4 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on September 3, 2024 at prices ranging from $1,175.35 to $1,175.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $1,174.32 | $9,394.56 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,745 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F3 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on September 3, 2024 at prices ranging from $1,174.14 to $1,174.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 16 | $1,172.75 | $18,764.00 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,753 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F2 · price: Represents volume-weighted average price of sales of 16 shares of Company stock on September 3, 2024 at prices ranging from $1,172.66 to $1,172.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 3, 2024 at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,170.40 | $4,681.60 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,769 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,168.99 | $4,675.96 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,773 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,167.27 | $1,167.27 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,777 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,166.52 | $4,666.08 |
DisclosureSEC source: 0001968202-24-000124 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,778 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,100.03 | $1,100.03 |
DisclosureSEC source: 0001968202-24-000111 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,782 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F2 · balance_after: Form two of two Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,099.65 | $3,298.95 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 30 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,783 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F18 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,099.49 to $1,099.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. F19 · balance_after: Form one of two Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,098.00 | $1,098.00 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 29 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,786 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,097.69 | $3,293.07 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 28 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,787 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F17 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,097.25 to $1,097.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,096.19 | $3,288.57 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 27 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,790 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F16 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,096.00 to $1,096.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,095.35 | $3,286.05 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 26 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,793 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F15 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,095.00 to $1,095.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,094.02 | $1,094.02 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 25 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,796 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $1,093.39 | $7,653.73 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 24 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,797 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F14 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on August 1, 2024 at prices ranging from $1,093.00 to $1,093.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $1,092.61 | $7,648.27 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 23 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,804 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F13 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on August 1, 2024 at prices ranging from $1,092.27 to $1,092.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13 | $1,091.47 | $14,189.11 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 22 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,811 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F12 · price: Represents volume-weighted average price of sales of 13 shares of Company stock on August 1, 2024 at prices ranging from $1,091.00 to $1,091.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $1,090.30 | $11,993.30 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 21 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,824 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F11 · price: Represents volume-weighted average price of sales of 11 shares of Company stock on August 1, 2024 at prices ranging from $1,090.00 to $1,090.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.